Browse > Article
http://dx.doi.org/10.15616/BSL.2021.27.4.208

A Review on the Correlation between the Pathology of Alzheimer's Disease and microRNA  

Kim, Soo-Jung (Department of Biomedical Laboratory Science, College of Medical Science, Konyang University)
Cho, Hyun-Jeong (Department of Biomedical Laboratory Science, College of Medical Science, Konyang University)
Publication Information
Biomedical Science Letters / v.27, no.4, 2021 , pp. 208-215 More about this Journal
Abstract
The purpose of this study was to explain the pathology of Alzheimer's disease (AD) and to investigate the correlation between AD and microRNA. AD is the most common type of dementia, accounting for about 80% of all types of dementia, causing dysfunction in various daily activities such as memory loss, cognitive impairment, and behavioral impairment. The typical pathology of AD is explained by the accumulation of beta-amyloid peptide plaques and neurofibrillary tangles containing hyperphosphorylated tau protein. On the other hand, microRNA is small non-coding RNA 22~23 nucleotides in length that binds to the 3' untranslated region of messenger RNA to inhibit gene expression. Many reports explain that microRNAs found in circulating biofluids are abundant in the central nervous system, are involved in the pathogenic mechanism of AD, and act as important factors for early diagnosis and therapeutic agents of AD. Therefore, this paper aims to clarify the correlation between AD and microRNA. In this review, the basic mechanism of miRNAs is described, and the regulation of miRNAs in the pathological processes of AD are highlighted. Furthermore, we suggest that miRNA-based system in development of therapeutic and diagnostic agents of AD can be a promising tool.
Keywords
Alzheimer's disease; Beta-amyloid plaques; Neurofibrillary tangles; MicroRNA; Biomarker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Amakiri N, Kubosumi A, Tran J, Reddy PH. Amyloid Beta and MicroRNAs in Alzheimer's Disease. Front Neurosci. 2019. 3: 430.
2 Pirscoveanu DFV, Pirici I, Tudorica VTudorica V et al. Tau protein in neurodegenerative diseases - a review. Rom J Morphol Embryol. 2017. 58: 1141-1150.
3 Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J. MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents? Front Pharmacol. 2019. 10: 665.   DOI
4 Athanasopoulos D, Karagiannis G, Tsolaki M. Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. Adv Nutr. 2016. 7: 917-927.   DOI
5 Auso E, Gomez-vicente V, Esquiva G. Biomarkers for Alzheimer's Disease Early Diagnosis. J Pers Med. 2020. 10: 114.   DOI
6 Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020. 25: 5789.   DOI
7 Canepa E, Fossati S. Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. Front Neurol. 2021. 11: 573324.   DOI
8 Cheignon C, Tomas M, Bonnefont-rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018. 14: 450-464.   DOI
9 Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018. 14: 399-415.   DOI
10 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement. 2020. 6: e12050.
11 Deng Y, Zhang J, Ma GMa G et al. miR-132 improves the cognitive function of rats with Alzheimer's disease by inhibiting the MAPK1 signal pathway. Exp Ther Med. 2020. 20: 159.   DOI
12 Eyileten C, Sharif L, Wicik ZWicik Z et al. The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Mol Neurobiol. 2021. 58: 329-347.   DOI
13 Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J. Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease. Med Sci Monit. 2019. 25: 3329-3335.   DOI
14 Kumar S, Reddy AP, Yin XYin X et al. Novel MicroRNA-455-3p and its Protective Effects Against Abnormal APP Processing and Amyloid Beta Toxicity in Alzheimer's Disease. Biochim Biophys Acta Mol Basis Dis. 2019. 1865: 2428-2440.   DOI
15 Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? Biochim Biophys Acta. 2016. 1862: 1617-1627.   DOI
16 Li J, Salvador AM, Li GLi G et al. Mir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling. Circ Res. 2021. 128: e1-e23.
17 Liu X, Wang H, Bei J, Zha J, Jiang G, Liu X. The protective role of miR-132 targeting HMGA2 through the PI3K/AKT pathway in mice with Alzheimer's disease. Am J Transl Res. 2021. 13: 4632-4643.
18 Lukiw WJ, Vergallo A, Lista S, Hampel H, Zhao Y. Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J Pers Med. 2020. 10: 138.   DOI
19 Mantzavinos V, Alexiou A. Biomarkers for Alzheimer's Disease Diagnosis. Curr Alzheimer Res. 2017. 14: 1149-1154.
20 Michalicova A, Majerova P, Kovac A. Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. Front Mol Neurosci. 2020. 13: 570045.   DOI
21 Naseri NN, Wang H, Guo J, Sharma M, Luo W. The complexity of tau in Alzheimer's disease. Neurosci Lett. 2019. 705: 183-194.   DOI
22 Prendecki M, Dorszewska J. The role of MicroRNA in the pathogenesis and diagnosis of neurodegenerative diseases. Austin Alzheimers J. Parkinsons Dis. 2014. 1: 10.
23 Rabbito A, Dulewicz M, Kulczynska-przybik A, Mroczko B. Biochemical Markers in Alzheimer's Disease. Int J Mol Sci. 2020. 21: 1989.   DOI
24 Rasgado LAV, Urbieta AT, Jimenez JMM. Affected albumin endocytosis as a new neurotoxicity mechanism of amyloid beta. AIMS neurosci. 2020. 7: 344-359.   DOI
25 Sheinerman KS, Toledo JB, Tsivinsky VGTsivinsky VG et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Res Ther. 2017. 9: 89.   DOI
26 Improta-Caria AC, Nonaka CKV, Cavalcante BRRCavalcante BRR et al. Modulation of MicroRNAs as a Potential Molecular Mechanism Involved in the Beneficial Actions of Physical Exercise in Alzheimer Disease. Int J Mol Sci. 2020. 21: 4977.   DOI
27 Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021. 20: 68-80.   DOI
28 Gugliandolo A, Chiricosta L, BoccardI V, Mecocci P, Bramanti P, Mazzon E. MicroRNAs Modulate the Pathogenesis of Alzheimer's Disease: An In Silico Analysis in the Human Brain. Genes. 2020. 11: 983.   DOI
29 Hamano T, Enomoto S, Shirafuji NShirafuji N et al. Autophagy and Tau Protein. Int J Mol Sci. 2021. 22: 7475.   DOI
30 Hara N, Kikuchi M, Miyashita AMiyashita A et al. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017. 5: 10.   DOI
31 Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer's Disease Biomarkers. Biomed Environ Sci. 2018. 31: 87-96.
32 FracassI A, MarcattI M, Zolochevska OZolochevska O et al. Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. J Neurosci. 2021. 41: 538-554.   DOI
33 Ghini F, Rubolino C, Climent M, Simeone I, Marzi MJ, Nicassio F. Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. Nat Commun. 2018. 9: 3119.   DOI
34 Guan P, Cao L, Wang P. Elevating the Levels of Calcium Ions Exacerbate Alzheimer's Disease via Inducing the Production and Aggregation of β-Amyloid Protein and Phosphorylated Tau. Int J Mol Sci. 2021. 22: 5900.   DOI
35 Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathological. 2020. 140: 417-447.   DOI
36 Kim E, Otgontenger U, Jamsranjav A, Kim SS. Deleterious Alteration of Glia in the Brain of Alzheimer's Disease. Int J Mol Sci. 2020. 21: 6676.   DOI
37 Jaber VR, Zhao Y, Sharfman NM, Li W, Lukiw WJ. Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies. Mol Neurobiol. 2019. 56: 8101-8108.   DOI
38 Soares Martins T, Trindade D, Vaz MVaz M et al. Diagnostic and therapeutic potential of exosomes in Alzheimer's disease. J Neurochem. 2021. 156: 162-181.   DOI
39 Swarbrick S, Wragg N, Ghosh S, Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer's Disease. Mol Neurobiol. 2019. 56: 6156-6167.   DOI
40 Vergallo A, Lista S, Zhao YZhao Y et al. MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. Transl Psychiatry. 2021. 11: 78.   DOI
41 Wang M, Qin L, Tang B. MicroRNAs in Alzheimer's Disease. Front Genet. 2019. 10: 153.   DOI
42 Wei W, Wang ZY, Ma LN, Zhang TT, Cao Y, Li H. MicroRNAs in Alzheimer's Disease: Function and Potential Applications as Diagnostic Biomarkers. Front Mol Neurosci. 2020. 13: 160.   DOI
43 Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000 Res. 2018. 7: Faculty Rev-1161.
44 Wu HZY, Thalamuthu A, Cheng LCheng L et al. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. Alzheimer's Res Ther. 2020. 12: 59.   DOI
45 Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain. 2019. 12: 26.   DOI
46 Zhao Y, Hampel H, Vergallo A, Lista S, Lukiw WJ. Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J Pers Med. 2020. 10: 138.   DOI
47 Zhou Q, Luo L, Wang X, Li X. Relationship between single nucleotide polymorphisms in the 3'UTR of amyloid precursor protein and risk of Alzheimer's disease and its mechanism. Biosci Rep. 2019. 39: BSR20182485.   DOI
48 Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018. 592: 2383-2391.   DOI
49 Guo Y, Wu Y, Li N, Wang Z. Up-regulation of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against β-amyloid by targeting DAPK-1 and TP53. Exp Mol Pathol. 2021. 118: 104587.   DOI
50 Huang Y, Mucke L. Alzheimer Mechanisms and Therapeutic Strategies. Cell. 2012. 148: 1204-1222.   DOI
51 Koh HS, Lee SJ, Lee HJLee HJ et al. Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. Int J Mol Sci. 2021. 22: 13136.   DOI
52 Kumar S, Reddy PH. MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update. Front Aging Neurosci. 2018. 10: 41.   DOI
53 Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018. 141: 1202-1207.   DOI
54 Manna I, De Benedittis S, Quattrone A, Maisano D, Iaccino E, Quattrone A. Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer's Disease. Pharmaceuticals. 2020. 13: 243.   DOI
55 Nasaruddin ML, Syarifah ASAH, Kamaruzzaman MA. Studying the Relationship of Intermittent Fasting and β-Amyloid in Animal Model of Alzheimer's Disease: A Scoping Review. Nutrients. 2020. 12: 3215.   DOI
56 Santa-Maria I, Alaniz ME, Renwick NRenwick N et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest. 2015. 125: 681-686.   DOI
57 Shi L, Zhang R, Li TLi T et al. Decreased miR-132 plays a crucial role in diabetic encephalopathy by regulating the GSK-3β/Tau pathway. Aging. 2020. 13: 4590-4604.
58 Van Giau V, An SS. Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease. J Neurol Sci. 2016. 360: 141-152.   DOI
59 Madadi S, Schwarzenbach H, Saidijam M, Mahjub R, Soleimani M. Potential microRNA-related targets in clearance pathways of amyloid-β: novel therapeutic approach for the treatment of Alzheimer's disease. Cell Biosci. 2019. 9: 91.   DOI
60 Chen F, Chen H, Jia Y, Lu H, Tan Q, Zhou X. miR-149-5p inhibition reduces Alzheimer's disease β-amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8. Exp Ther Med. 2020. 20: 88.
61 Wang X, Zhou Y, Gao QGao Q et al. The Role of Exosomal microRNAs and Oxidative Stress in Neurodegenerative Diseases. Oxid Med Cell Longev. 2020. 3232869.
62 Wilkins HM, Swerdlow RH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull. 2017. 133: 71-79.   DOI
63 Yu L, Li H, Liu WLiu W et al. MiR-485-3p serves as a biomarker and therapeutic target of Alzheimer's disease via regulating neuronal cell viability and neuroinflammation by targeting AKT3. Mol Genet Genomic Med. 2021. 9: e1548.
64 Zhao Y, Jaber V, Alexandrov PNAlexandrov PN et al. microRNA-Based Biomarkers in Alzheimer's Disease. Front Neurosci. 2020. 14: 585432.   DOI